BUZZ-Aardvark Therapeutics falls after pausing late-stage rare disease trial
Reuters
Feb 28
BUZZ-<a href="https://laohu8.com/S/AARD">Aardvark Therapeutics</a> falls after pausing late-stage rare disease trial
** Shares of drug developer Aardvark TherapeuticsAARD.O fall 47.2% to $6.58 aftermarkets
** Co says it is voluntarily pausing its late-stage trial testing its experimental treatment for a type of rare genetic disease
** Says decision was made after it found heart-related side effects during safety monitoring in a healthy volunteer study in patients receiving higher‑than‑planned doses of the treatment
** Says no longer anticipates announcing topline data from the trial in the third quarter of 2026
** Stock has fallen 12.6% since its Nasdaq debut last year
(Reporting by Sneha S K)
((Sneha.SK@thomsonreuters.com;))
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.